BRCA1 and pancreatic neoplasm: Whole-genome sequencing of 15 pancreatic cancers deliberately enriched for cases with BRCA1/2 mutations revealed the presence of signature 3 in six samples (40.0%), while examination of an unbiased set of 216 whole-exome sequenced pancreatic cancers identified signature 3 in 16 cases (∼7.41%).